AAAAAA

   
Results: 1-25 | 26-26
Results: 1-25/26
Cellular and biophysical evidence for interactions between adenosine triphosphate and P-glycoprotein substrates: functional implications for adenosine triphosphate/drug cotransport in P-glycoprotein overexpressing tumor cells and in P-glycoprotein low-level expressing erythrocytes
Authors: Abraham, EH Shrivastav, B Salikhova, AY Sterling, KM Johnston, N Guidotti, G Scala, S Litman, T Chan, KC Arceci, RJ Steiglitz, K Herscher, L Okunieff, P
Citation: Eh. Abraham et al., Cellular and biophysical evidence for interactions between adenosine triphosphate and P-glycoprotein substrates: functional implications for adenosine triphosphate/drug cotransport in P-glycoprotein overexpressing tumor cells and in P-glycoprotein low-level expressing erythrocytes, BL CELL M D, 27(1), 2001, pp. 181-200
Loss and hope
Authors: Arceci, RJ
Citation: Rj. Arceci, Loss and hope, J PED H ONC, 23(8), 2001, pp. 475-475
Dr. Louis K. Diamond: Jewel in the crown of pediatric hematology
Authors: Arceci, RJ
Citation: Rj. Arceci, Dr. Louis K. Diamond: Jewel in the crown of pediatric hematology, J PED H ONC, 23(6), 2001, pp. 333-333
Comments from the editor-in-chief
Authors: Arceci, RJ
Citation: Rj. Arceci, Comments from the editor-in-chief, J PED H ONC, 23(4), 2001, pp. 195-196
An SNF2 factor involved in mammalian development and cellular proliferation
Authors: Raabe, EH Abdurrahman, L Behbehani, G Arceci, RJ
Citation: Eh. Raabe et al., An SNF2 factor involved in mammalian development and cellular proliferation, DEV DYNAM, 221(1), 2001, pp. 92-105
Activating mutations of c-kit at codon 816 confer drug resistance in humanleukemia cells
Authors: Ning, ZQ Li, J Arceci, RJ
Citation: Zq. Ning et al., Activating mutations of c-kit at codon 816 confer drug resistance in humanleukemia cells, LEUK LYMPH, 41(5-6), 2001, pp. 513-522
STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity
Authors: Ning, ZQ Li, J McGuinness, M Arceci, RJ
Citation: Zq. Ning et al., STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity, ONCOGENE, 20(33), 2001, pp. 4528-4536
Preface
Authors: Arceci, RJ Coppes, MJ Tubergen, DG
Citation: Rj. Arceci et al., Preface, HEMAT ONCOL, 15(4), 2001, pp. XI-XII
Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells
Authors: Ning, ZQ Li, J Arceci, RJ
Citation: Zq. Ning et al., Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells, BLOOD, 97(11), 2001, pp. 3559-3567
Comments from the editor-in-chief
Authors: Arceci, RJ
Citation: Rj. Arceci, Comments from the editor-in-chief, J PED H ONC, 22(6), 2000, pp. 489-489
Comments from the editor-in-chief
Authors: Arceci, RJ
Citation: Rj. Arceci, Comments from the editor-in-chief, J PED H ONC, 22(4), 2000, pp. 295-295
Comments from the editor-in-chief
Authors: Arceci, RJ
Citation: Rj. Arceci, Comments from the editor-in-chief, J PED H ONC, 22(2), 2000, pp. 97-97
Response to letters to the Editor from the Editor-in-Chief
Authors: Arceci, RJ
Citation: Rj. Arceci, Response to letters to the Editor from the Editor-in-Chief, J PED H ONC, 22(2), 2000, pp. 186-187
Comments from the editor-in-chief
Authors: Arceci, RJ
Citation: Rj. Arceci, Comments from the editor-in-chief, J PED H ONC, 22(1), 2000, pp. 1-2
Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia
Authors: Dahl, GV Lacayo, NJ Brophy, N Dunussi-Joannopoulos, K Weinstein, HJ Chang, MR Sikic, BI Arceci, RJ
Citation: Gv. Dahl et al., Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia, J CL ONCOL, 18(9), 2000, pp. 1867-1875
Proliferation-associated SNF2-like gene (PASG): A SNF2 family member altered in leukemia
Authors: Lee, DW Zhang, KJ Ning, ZQ Raabe, EH Tintner, S Wieland, R Wilkins, BJ Kim, JM Blough, RI Arceci, RJ
Citation: Dw. Lee et al., Proliferation-associated SNF2-like gene (PASG): A SNF2 family member altered in leukemia, CANCER RES, 60(13), 2000, pp. 3612-3622
Can multidrug resistance mechanisms be modified?
Authors: Arceci, RJ
Citation: Rj. Arceci, Can multidrug resistance mechanisms be modified?, BR J HAEM, 110(2), 2000, pp. 285-291
Comments from the editor-in-chief
Authors: Arceci, RJ
Citation: Rj. Arceci, Comments from the editor-in-chief, J PED H ONC, 21(6), 1999, pp. 459-460
Dr. Louis Diamond: A career of saving babies
Authors: Arceci, RJ
Citation: Rj. Arceci, Dr. Louis Diamond: A career of saving babies, J PED H ONC, 21(5), 1999, pp. 343-343
Iron: Still fascinating after all these years
Authors: Arceci, RJ
Citation: Rj. Arceci, Iron: Still fascinating after all these years, J PED H ONC, 21(5), 1999, pp. 343-343
Comments from the editor-in-chief
Authors: Arceci, RJ
Citation: Rj. Arceci, Comments from the editor-in-chief, J PED H ONC, 21(2), 1999, pp. 85-86
Predictors of response in leukemia - Comment
Authors: Arceci, RJ
Citation: Rj. Arceci, Predictors of response in leukemia - Comment, J PED H ONC, 21(1), 1999, pp. 1-2
The histiocytoses: The fall of the Tower of Babel
Authors: Arceci, RJ
Citation: Rj. Arceci, The histiocytoses: The fall of the Tower of Babel, EUR J CANC, 35(5), 1999, pp. 747-767
Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance (vol 16, pg 3674, 1998)
Authors: Bradshaw, DM Arceci, RJ
Citation: Dm. Bradshaw et Rj. Arceci, Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance (vol 16, pg 3674, 1998), J CL ONCOL, 17(4), 1999, pp. 1330-1330
Congenital and neonatal leukemia
Authors: Sande, JE Arceci, RJ Lampkin, BC
Citation: Je. Sande et al., Congenital and neonatal leukemia, SEM PERINAT, 23(4), 1999, pp. 274-285
Risultati: 1-25 | 26-26